Facilities
Our Pilot Plant is an independent, small scale FDA approved production facility counting more than 25 reactors and vessels from 50 to 650 L for a total of 6 m3 capacity.
3 different and fully segregated clean zones for final APIs processing enable 3 parallel projects to run independently. Pilot Plant operations are designed and maintained an exactly the same standard as the production environment at the target commercial scale, which ensures a smooth process transfer at a larger scale (same quality, EHS standards, format for Batch records and SOP’s are applied as for production areas).
This facility runs 24h/day and 7 days/week and giving its capacity and flexibility is used for both scale-up studies to prove process robustness and also routine manufacturing of relatively small volume commercial API. Polpharma's efforts in cost-efficiency and innovation ensure the continued...
Latest updates

Ryvu Therapeutics and Polpharma sign two agreements in the area of RVU120 API production for Phase II clinical trials
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology and Zakłady Farmaceutyczne Po
Learn more
Another Polpharma API strategic milestone achieved!
Another Polpharma API strategic milestone achieved! ‍ KiloLab Laboratory - a development and production in a kilogram scale - has been launche
Learn more
First CADIFA certification from ANVISA for Etodolac
In the dynamic landscape of pharmaceutical regulations, Brazil took a significant stride in April 2020 when ANVISA unveiled new rules about active pharmaceutical ingredients (APIs). Fast forward to Au
Learn more
Rising Prevalence of Cancer and Its Impact on the HP API Market
Cancer cases are expected to increase by 61% by 2050, particularly in lower-income countries. This alarming trend underscores the urgent need for more effective and targeted treatment options. In resp
Learn more
Polpharma Group's environmental responsibility
We understand that a healthy world that we strive to contribute to through our mission includes a healthy environment. As a manufacturing company, we are committed to reducing our environmental impact
Learn more
An Overview of Breast Cancer: Understanding Risks, Treatments, and Market Trends
Breast cancer is a disease characterized by the uncontrolled growth of cells in the breast tissue. It is the second most common cancer type overall, and the most prevalent cancer among women worldwide
Learn more
Polpharma's HP API facility is live!
An extraordinary investment in the API sector - a new facility adapted to work with highly potent active pharmaceutical ingredients (HP API), the first and only of its kind in Poland.
Learn more
Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
In the relentless pursuit of excellence and delivering top-quality products, the pharmaceutical industry often relies on established facts and practices. However, thi
Learn more
A Comprehensive Overview and Prognosis of the Diabetes Market
Diabetes is one of the most serious health problems in the modern world.
Learn more
Welcoming Pere Mañé as Suanfarma’s New CEO
Suanfarma Appoints Pere Mane as New CEO to Drive Industrial Growth and Global Expansion
Learn moreUpcoming events

DCAT 2025
In-person event17-03-2025

World ADC London 2025
In-person event03-03-2025




World ADC San Diego
In-person event03-11-2025

CPHI WW 2025 Frankfurt
In-person event28-10-2025

CPHI China 2025
In-person event24-06-2025
Services
- New chemical routes full development
- Process optimization
- Technical transfer
- Analytical methods development, transfer, validation
- Troubleshooting
- Crystallization studies
- Particle size distribution control
Our Pilot Plant is an independent, small scale FDA approved production facility counting...
Drug Substance (CDMO/CRO)
Replies quickly
Replies quickly
Replies quickly
Replies quickly
Replies quickly
Contact Polpharma for Contract Services Expertise
Connect with Polpharma, a leading pharmaceutical company from Poland. They offer specialized Drug Substance (CDMO/CRO). Contact Polpharma for free and discover if they are the perfect partner for your pharmaceutical needs.
Drug Substance (CDMO/CRO)
Drug Substance CDMOs and CROs provide essential services in the development and manufacturing of active pharmaceutical ingredients (APIs). These organizations specialize in early-stage research, process development, and GMP-compliant manufacturing of drug substances for clinical and commercial use.
Pharmaoffer's Drug Substance CDMO/CRO category includes partners with expertise in small molecules, biologics, peptides, and complex chemistry, all operating under strict regulatory compliance. These providers help companies scale from lab to market efficiently and cost-effectively.
Key Functions of Drug Substance CDMOs/CROs:
API Research and Development: Providing early-stage discovery support, custom synthesis, and process optimization to streamline the development of drug substances.
Process Scale-Up and Tech Transfer: Transitioning from bench-scale to pilot and commercial scale production with validated methods and reproducibility.
GMP Manufacturing: Delivering high-quality API batches in GMP-certified environments, adhering to FDA, EMA, and other international standards.
Analytical Services: Offering comprehensive analytical method development and validation to ensure consistent quality and regulatory compliance.
Flexible and Specialized Capabilities: From small molecule synthesis to biologic and peptide manufacturing, these partners provide specialized services tailored to product-specific needs.
Explore Leading API CDMOs and CROs
Pharmaoffer connects you with trusted CDMOs and CROs for drug substance development. Our platform enables seamless access to specialized service providers equipped to support your API lifecycle from discovery to commercialization.